- Home
- JRVR vs TKNO Comparison
JRVR vs TKNO Comparison
Compare JRVR & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | TKNO |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 268.1M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JRVR | TKNO |
|---|---|---|
| Price | $3.53 | $9.33 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.33 | N/A |
| AVG Volume (30 Days) | ★ 252.2K | 201.7K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | 43.86 |
| EPS | N/A | N/A |
| Revenue | ★ $687,614,000.00 | $40,520,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | $1.61 | $13.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.35 |
| 52 Week Low | $3.52 | $1.91 |
| 52 Week High | $7.20 | $9.41 |
Technical Indicators
Market Signals| Indicator | JRVR | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 27.71 | 80.33 |
| Support Level | N/A | $2.71 |
| Resistance Level | $4.26 | N/A |
| Average True Range (ATR) | 0.13 | 0.51 |
| MACD | -0.03 | 0.21 |
| Stochastic Oscillator | 6.30 | 94.13 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.